Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) does about 2.00M shares in volume on a normal day but saw 1482450 shares change hands in Friday trading. The company now has a market cap of 221.88M USD. Its current market price is $0.98, marking an increase of 8.72% compared to the previous close of $0.90. The 52 week high reached by this stock is $2.05 whilst the lowest price level in 52 weeks is $0.42.
Adaptimmune Therapeutics Plc ADR (ADAP) has a 20-day trading average at $1.2961 and the current price is -52.36% off the 52-week high compared with 132.55% distance from its 52-week low. The 50-day simple moving average of the closing price is $1.3889 and its 200-day simple moving average is $0.8926. If we look at the stock’s price movements over the week, volatility stands at 13.75%, which decreases to 9.64% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 32.27 to suggest the stock is neutral.
The consensus objective for the share price is $3.50, suggesting that the stock has a potential upside of 72.0% over the period.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on March 24, 2023 when Bryan Garnier initiated the stock to “Buy” and issued a price target of $3.60. Guggenheim upgraded the stock to “Buy” from Neutral on January 03, 2023 at a price target of $5. Mizuho upgraded its price target at $9.
Adaptimmune Therapeutics Plc ADR (ADAP) stock is down -15.80% over the week and -26.56% over the past month. Its price is 23.17% year-to-date and -35.32% over the past year.
To reach the target analysts have set, the stock logically needs to grow 72.0 percent from here.
The company has a return on investment of -192.17% and return on equity of -187.96%. The beta has a value of 2.49. Price to book ratio is 5.62 and price to sales ratio is 3.66.
